Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the month of January 2022, with a specific reporting date of January 20, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Instrument | Transaction Type | Price (USD) | Total Volume (ADSs) | Date |
|---|---|---|---|---|
| American Depositary Shares (ADSs) | Acquisition via Dividend Re-investment | $46.2266 | 2,696.591 | 2022-01-19 |
Note: The total volume represents the aggregate of four separate transactions executed on the same date at the same price.
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It documents routine compliance disclosures for dividend reinvestment plans.
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transactions were executed on the New York Stock Exchange (XNYS) following the re-investment of dividends paid to shareholders on January 13, 2022.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ADSs resulting from the automatic re-investment of dividends, not open-market purchases or sales.
- Participants: The transactions involved four executives: Dr. H. Barron (CSO & President, R&D), Mr. J. Ford (SVP & General Counsel), Mr. B. McNamara (CEO, GSK Consumer Healthcare), and Shobie Ramakrishnan (Chief Digital & Technology Officer).
- Market Price: The ADSs were acquired at a uniform price of $46.2266 per share.
- Financial Data: This document does not provide any company-wide financial performance data (e.g., revenue, earnings, cash flow).